pyrroles has been researched along with taxane in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, BJ; Baum, CM; Bello, CL; Burstein, HJ; Cobleigh, MA; DePrimo, SE; Eisenberg, PD; Elias, AD; Lehman, M; Miller, KD; Rugo, HS; Wolff, AC | 1 |
| Aogi, K; Arioka, H; Fujii, H; Fujiwara, Y; Inoue, K; Ito, Y; Iwata, H; Saeki, T; Suzuki, Y; Takatsuka, Y; Toi, M; Tokuda, Y; Watanabe, T | 1 |
2 trial(s) available for pyrroles and taxane
| Article | Year |
|---|---|
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Indoles; Middle Aged; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Survival Rate; Taxoids | 2008 |
A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Middle Aged; Neovascularization, Pathologic; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |